{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T11:14:38Z","timestamp":1761909278059,"version":"build-2065373602"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-03796-2","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:33:20Z","timestamp":1761564800000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Factors associated with taxane-associated acute pain syndrome in pancreatic cancer patients receiving gemcitabine and nab-paclitaxel"],"prefix":"10.1007","volume":"16","author":[{"given":"Yoshitaka","family":"Saito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoh","family":"Takekuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshito","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuru","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"3796_CR1","doi-asserted-by":"publisher","first-page":"8059","DOI":"10.1007\/s00520-021-06342-2","volume":"29","author":"Y Saito","year":"2021","unstructured":"Saito Y, Takekuma Y, Kobayashi M, Sakamoto T, Yamashita H, Sugawara M. Risk factor analysis for taxane-associated acute pain syndrome under the dexamethasone prophylaxis. Support Care Cancer. 2021;29:8059\u201367. https:\/\/doi.org\/10.1007\/s00520-021-06342-2.","journal-title":"Support Care Cancer"},{"key":"3796_CR2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00520-019-04808-y","volume":"28","author":"Y Saito","year":"2020","unstructured":"Saito Y, Kobayashi M, Yamada T, Sakakibara-Konishi J, Shinagawa N, Kinoshita I, et al. Efficacy of additional dexamethasone administration for the attenuation of paclitaxel-associated acute pain syndrome. Support Care Cancer. 2020;28:221\u20137. https:\/\/doi.org\/10.1007\/s00520-019-04808-y.","journal-title":"Support Care Cancer"},{"key":"3796_CR3","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1007\/s00520-016-3256-5","volume":"24","author":"R Fernandes","year":"2016","unstructured":"Fernandes R, Mazzarello S, Hutton B, Shorr R, Majeed H, Ibrahim MF, et al. Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer-a systematic review. Support Care Cancer. 2016;24:3633\u201350. https:\/\/doi.org\/10.1007\/s00520-016-3256-5.","journal-title":"Support Care Cancer"},{"key":"3796_CR4","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s11864-025-01302-y","volume":"26","author":"Y Saito","year":"2025","unstructured":"Saito Y. Taxane-associated acute pain syndrome: a review of its features and management. Curr Treat Options Oncol. 2025;26:187\u201396. https:\/\/doi.org\/10.1007\/s11864-025-01302-y.","journal-title":"Curr Treat Options Oncol"},{"key":"3796_CR5","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691\u2013703. https:\/\/doi.org\/10.1056\/NEJMoa1304369.","journal-title":"N Engl J Med"},{"key":"3796_CR6","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s00280-016-2972-3","volume":"77","author":"H Ueno","year":"2016","unstructured":"Ueno H, Ikeda M, Ueno M, Mizuno N, Ioka T, Omuro Y, et al. Phase I\/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2016;77:595\u2013603. https:\/\/doi.org\/10.1007\/s00280-016-2972-3.","journal-title":"Cancer Chemother Pharmacol"},{"key":"3796_CR7","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12885-018-5244-2","volume":"19","author":"H Blomstrand","year":"2019","unstructured":"Blomstrand H, Scheibling U, Bratth\u00e4ll C, Green H, Elander NO. Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer. BMC Cancer. 2019;19:40. https:\/\/doi.org\/10.1186\/s12885-018-5244-2.","journal-title":"BMC Cancer"},{"key":"3796_CR8","unstructured":"Highlights, of prescribing information these highlights do not include all the information needed to use Abraxane safely and effectively. See full prescribing information for ABRAXANE. ABRAXANE\u00ae for injectable suspension (paclitaxel protein-bound particles for injectable suspension). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/021660s047lbl.pdf"},{"key":"3796_CR9","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1007\/s00520-018-4571-9","volume":"27","author":"Y Kanbayashi","year":"2019","unstructured":"Kanbayashi Y, Sakaguchi K, Nakatsukasa K, Ouchi Y, Tabuchi Y, Yoshioka T, et al. Predictive factors for taxane acute pain syndrome determined by ordered logistic regression analysis. Support Care Cancer. 2019;27:2673\u20137. https:\/\/doi.org\/10.1007\/s00520-018-4571-9.","journal-title":"Support Care Cancer"},{"key":"3796_CR10","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1007\/s00520-023-07852-x","volume":"31","author":"Y Saito","year":"2023","unstructured":"Saito Y, Takekuma Y, Takeshita T, Oshino T, Sugawara M. Dexamethasone dose-dependently prevents taxane-associated acute pain syndrome in breast cancer treatment. Support Care Cancer. 2023;31:372. https:\/\/doi.org\/10.1007\/s00520-023-07852-x.","journal-title":"Support Care Cancer"},{"key":"3796_CR11","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1006\/gyno.1998.5226","volume":"72","author":"M Markman","year":"1999","unstructured":"Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Use of low-dose oral prednisone to prevent paclitaxel-induced arthralgias and myalgias. Gynecol Oncol. 1999;72:100\u20131. https:\/\/doi.org\/10.1006\/gyno.1998.5226.","journal-title":"Gynecol Oncol"},{"key":"3796_CR12","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s00520-008-0508-z","volume":"17","author":"T Yoshida","year":"2009","unstructured":"Yoshida T, Sawa T, Ishiguro T, Horiba A, Minatoguchi S, Fujiwara H. The efficacy of prophylactic Shakuyaku-Kanzo-to for myalgia and arthralgia following carboplatin and Paclitaxel combination chemotherapy for non-small cell lung cancer. Support Care Cancer. 2009;17:315\u201320. https:\/\/doi.org\/10.1007\/s00520-008-0508-z.","journal-title":"Support Care Cancer"},{"key":"3796_CR13","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1200\/JCO.2004.99.298","volume":"22","author":"VH Nguyen","year":"2004","unstructured":"Nguyen VH, Lawrence HJ. Use of gabapentin in the prevention of taxane-induced arthralgias and myalgias. J Clin Oncol. 2004;22:1767\u20139. https:\/\/doi.org\/10.1200\/JCO.2004.99.298.","journal-title":"J Clin Oncol"},{"key":"3796_CR14","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.1007\/s00520-017-3760-2","volume":"25","author":"DR Pachman","year":"2017","unstructured":"Pachman DR, Dockter T, Zekan PJ, Fruth B, Ruddy KJ, Ta LE, et al. A pilot study of minocycline for the prevention of paclitaxel-associated neuropathy: ACCRU study RU221408I. Support Care Cancer. 2017;25:3407\u201316. https:\/\/doi.org\/10.1007\/s00520-017-3760-2.","journal-title":"Support Care Cancer"},{"key":"3796_CR15","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ejca.2022.05.019","volume":"171","author":"J Zhang","year":"2022","unstructured":"Zhang J, Gao HF, Yang C, Zhu T, Ji F, Yang M, et al. Prevention of taxane-associated acute pain syndrome with etoricoxib for patients with breast cancer: a phase II randomised trial. Eur J Cancer. 2022;171:150\u201360. https:\/\/doi.org\/10.1016\/j.ejca.2022.05.019.","journal-title":"Eur J Cancer"},{"key":"3796_CR16","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s10147-024-02535-x","volume":"29","author":"H Iihara","year":"2024","unstructured":"Iihara H, Abe M, Wada M, Iino K, Akechi T, Imamura CK, et al. 2023 Japan society of clinical oncology clinical practice guidelines update for antiemesis. Int J Clin Oncol. 2024;29:873\u201388. https:\/\/doi.org\/10.1007\/s10147-024-02535-x.","journal-title":"Int J Clin Oncol"},{"key":"3796_CR17","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00520-019-04845-7","volume":"28","author":"R Asthana","year":"2020","unstructured":"Asthana R, Zhang L, Wan BA, Gallo-Hershberg D, Giotis A, Pasetka M, et al. Pain descriptors of taxane acute pain syndrome (TAPS) in breast cancer patients-a prospective clinical study. Support Care Cancer. 2020;28:589\u201398. https:\/\/doi.org\/10.1007\/s00520-019-04845-7.","journal-title":"Support Care Cancer"},{"key":"3796_CR18","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1080\/14656566.2021.1901885","volume":"22","author":"JV Pergolizzi","year":"2021","unstructured":"Pergolizzi JV, Magnusson P, LeQuang JA, Breve F, Taylor R, Wollmuth C, Varrassi G. Can NSAIDs and acetaminophen effectively replace opioid treatment options for acute pain? Expert Opin Pharmacother. 2021;22:1119\u201326. https:\/\/doi.org\/10.1080\/14656566.2021.1901885.","journal-title":"Expert Opin Pharmacother"},{"key":"3796_CR19","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/ALN.0000000000001700","volume":"127","author":"N Ohashi","year":"2017","unstructured":"Ohashi N, Uta D, Sasaki M, Ohashi M, Kamiya Y, Kohno T. Acetaminophen metabolite N-acylphenolamine induces analgesia via transient receptor potential vanilloid 1 receptors expressed on the primary afferent terminals of C-fibers in the spinal dorsal horn. Anesthesiology. 2017;127:355\u201371. https:\/\/doi.org\/10.1097\/ALN.0000000000001700.","journal-title":"Anesthesiology"},{"key":"3796_CR20","doi-asserted-by":"publisher","first-page":"580289","DOI":"10.3389\/fphar.2020.580289","volume":"11","author":"N Ohashi","year":"2020","unstructured":"Ohashi N, Kohno T. Analgesic effect of acetaminophen: a review of known and novel mechanisms of action. Front Pharmacol. 2020;11:580289. https:\/\/doi.org\/10.3389\/fphar.2020.580289.","journal-title":"Front Pharmacol"},{"key":"3796_CR21","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/s0304-3940(01)02093-6","volume":"310","author":"SM Carlton","year":"2001","unstructured":"Carlton SM, Coggeshall RE. Peripheral capsaicin receptors increase in the inflamed rat hindpaw: a possible mechanism for peripheral sensitization. Neurosci Lett. 2001;310:53\u20136. https:\/\/doi.org\/10.1016\/s0304-3940(01)02093-6.","journal-title":"Neurosci Lett"},{"key":"3796_CR22","doi-asserted-by":"publisher","first-page":"5171","DOI":"10.1002\/cncr.27489","volume":"118","author":"BN Reeves","year":"2012","unstructured":"Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, Kamal A, et al. Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy: North central cancer treatment group trial N08C1. Cancer. 2012;118:5171\u20138. https:\/\/doi.org\/10.1002\/cncr.27489.","journal-title":"Cancer"},{"key":"3796_CR23","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00520-017-3836-z","volume":"26","author":"N Chiu","year":"2018","unstructured":"Chiu N, Zhang L, Dent R, Giotis A, van Draanen J, Gallo-Hershberg D, et al. A prospective study of docetaxel-associated pain syndrome. Support Care Cancer. 2018;26:203\u201311. https:\/\/doi.org\/10.1007\/s00520-017-3836-z.","journal-title":"Support Care Cancer"},{"key":"3796_CR24","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1200\/JCO.2010.33.0308","volume":"29","author":"CL Loprinzi","year":"2011","unstructured":"Loprinzi CL, Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, et al. Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol. 2011;29:1472\u20138. https:\/\/doi.org\/10.1200\/JCO.2010.33.0308.","journal-title":"J Clin Oncol"},{"key":"3796_CR25","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1007\/s00520-020-05842-x","volume":"29","author":"Y Saito","year":"2021","unstructured":"Saito Y, Takekuma Y, Kobayashi M, Komatsu Y, Sugawara M. Detection of risk factors related to administration suspension and severe neutropenia in gemcitabine and nab-paclitaxel treatment. Support Care Cancer. 2021;29:3277\u201385. https:\/\/doi.org\/10.1007\/s00520-020-05842-x.","journal-title":"Support Care Cancer"},{"key":"3796_CR26","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.1200\/JCO.2011.36.5742","volume":"29","author":"DD Von Hoff","year":"2011","unstructured":"Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I\/II trial. J Clin Oncol. 2011;29:4548\u201354. https:\/\/doi.org\/10.1200\/JCO.2011.36.5742.","journal-title":"J Clin Oncol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03796-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-03796-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03796-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T11:11:59Z","timestamp":1761909119000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-03796-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3796"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-03796-2","relation":{},"ISSN":["2730-6011"],"issn-type":[{"type":"electronic","value":"2730-6011"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"13 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures involving human participants performed in this study were carried out in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. For this type of study, formal consent was waived by the Ethical Review Board for Life Science and Medical Research of the Hokkaido University Hospital.For this type of study, formal consent was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and\u00a0consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"YS, YT, and MS have no conflicts of interest. YK reports grants and personal fees from Ono, Taiho, Chugai, Eli Lilly, Daiichi Sankyo, Nippon Kayaku, and MSD; personal fees from Bayer and Yakult; and grants from IQVIA, Astellas, Nippon Zoki, Shionogi, EPS, Eisai, and the National Cancer Center outside of the submitted work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1967"}}